Compare FTRE & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTRE | CII |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2023 | N/A |
| Metric | FTRE | CII |
|---|---|---|
| Price | $18.04 | $25.80 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $14.06 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 61.3K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,723,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.00 | N/A |
| 52 Week Low | $4.46 | $20.43 |
| 52 Week High | $18.67 | $26.17 |
| Indicator | FTRE | CII |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 62.20 |
| Support Level | $15.40 | $23.04 |
| Resistance Level | $18.13 | $26.14 |
| Average True Range (ATR) | 0.90 | 0.44 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 80.00 | 87.41 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.